| Rubius Therapeutics is a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to develop a class of cellular medicines called Red Cell Therapeutics for the treatment of cancer and autoimmune diseases. Co.'s platform, RED PLATFORM, biologically engineers and cultures allogeneic red blood cell therapies that enable multiple applications, or modalities. Co.'s immune stimulation for the treatment of cancer includes RTX-240, which is designed to stimulate the immune system by activating and expanding both NK and CD8+ memory T cells to generate an anti-tumor response; and RTX-224, which is designed as an immune agonist of both adaptive and innate responses. We show 20 historical shares outstanding datapoints in our coverage of RUBY's shares outstanding history.|
Understanding the changing numbers of RUBY shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like RUBY versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching RUBY by allowing them to research RUBY shares outstanding history
as well as any other stock in our coverage universe.